Log In
BCIQ
Print this Print this
 

Lu AF20513

  Manage Alerts
Collapse Summary General Information
Company H. Lundbeck A/S
DescriptionHigh affinity polyclonal antibody against beta amyloid
Molecular Target Beta amyloid
Mechanism of ActionVaccine; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
PartnerOtsuka Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$5.5M

$205.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/16/2013

$5.5M

$5.5M

0

11/14/2011

Undisclosed

$200.0M

Undisclosed

Get a free BioCentury trial today